Alpha Tau Medical (DRTS) Total Non-Current Liabilities (2020 - 2026)
Alpha Tau Medical's (DRTS) quarterly Total Non-Current Liabilities came in at $29.0 million in Q1 2026, up 95.28% year-on-year from $14.8 million in Q1 2025, and up 60.55% quarter-over-quarter from $18.0 million in Q4 2025.
Alpha Tau Medical (DRTS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Alpha Tau Medical has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $29.0 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $29.0 million, up 95.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.0 million (up 95.28% YoY), and the FY2025 annual result was $18.0 million, up 21.42% from the prior year.
- Total Non-Current Liabilities came in at $29.0 million for Q1 2026 at Alpha Tau Medical, up from $18.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $29.0 million in Q1 2026 to a low of $10.2 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $15.3 million (2024), against an average of $15.7 million.
- Across the five-year window, Total Non-Current Liabilities surged 130.51% in 2022 and slipped 9.41% in 2025, its largest moves.
- Alpha Tau Medical's Total Non-Current Liabilities stood at $10.2 million in 2022, then jumped by 55.71% to $15.8 million in 2023, then decreased by 6.0% to $14.9 million in 2024, then increased by 21.42% to $18.0 million in 2025, then surged by 60.55% to $29.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $29.0 million (Q1 2026), $18.0 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 42,980.09 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 64.76 Mn |
| 10 | Alpha Tau Medical | 2,384.20 | -76.42 Mn | - | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.97 Mn |
| Dec 31, 2025 | 18.05 Mn |
| Sep 30, 2025 | 17.97 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 14.84 Mn |
| Dec 31, 2024 | 14.86 Mn |
| Sep 30, 2024 | 14.98 Mn |
| Jun 30, 2024 | 15.58 Mn |
| Mar 31, 2024 | 16.38 Mn |
| Dec 31, 2023 | 15.81 Mn |
| Sep 30, 2023 | 10.65 Mn |
| Jun 30, 2023 | 13.23 Mn |
| Mar 31, 2023 | 11.55 Mn |
| Dec 31, 2022 | 10.15 Mn |
| Dec 31, 2021 | 4.41 Mn |
| Dec 31, 2020 | 2.09 Mn |